Defective Drugs

Zantac found to be potential cancer risk by FDA due to NDMA Carcinogen

This page features: Cited Research Articles The FDA announced on September 13, 2019, that low levels of a probable human carcinogen called N-nitrosodimethlylamine (NDMA), are found in Zantac (ranitidine). Then, on January 8, 2020, the FDA alerted patients and health care professionals of two voluntary recalls of the drug known by the name of Zantac (ranitidine) …

Zantac found to be potential cancer risk by FDA due to NDMA Carcinogen Read More »

FDA Issues Safety Warning Due to Increased Death Rates From Febuxostat

This page features: Cited Research Articles In February of 2019, the FDA issued a new black box warning for the medication febuxostat, which users currently take for gout. The warning states that patients who take the drug are at an increased risk of death due to heart related complications. A recent report showed 15 recent deaths …

FDA Issues Safety Warning Due to Increased Death Rates From Febuxostat Read More »

Total Body Bone Loss Reported In A Single Arm Adolescent Study on Truvada

This page features: Cited Research Articles A recent study in Clinical Infectious diseases suggested that patients between the ages of 15 and 19 years of age taking PrEP for HIV prevention, may not recover from bone mineral density loss.  Of particular concern, is that the damage was incurred in the lumbar spine region and whole body …

Total Body Bone Loss Reported In A Single Arm Adolescent Study on Truvada Read More »